Dyne Therapeutics Partners with Pfizer for DMD Drug
Ticker: DYN · Form: 8-K · Filed: May 20, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | 8-K |
| Filed Date | May 20, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: collaboration, drug-development, rare-disease
Related Tickers: PFE
TL;DR
Dyne teams up with Pfizer to test their DMD drug DYNE-251, big news for rare disease treatment.
AI Summary
Dyne Therapeutics, Inc. announced on May 20, 2024, that it has entered into a clinical collaboration with Pfizer Inc. to evaluate Dyne's novel antibody-oligonucleotide conjugate (AOC) therapeutic candidate, DYNE-251, for the treatment of Duchenne muscular dystrophy (DMD) in individuals with specific mutations. This collaboration will leverage Pfizer's expertise in gene therapy and DMD research to advance the development of DYNE-251.
Why It Matters
This collaboration with a major pharmaceutical company like Pfizer could significantly accelerate the development and potential approval of Dyne's promising drug for a rare and serious disease, offering hope to patients.
Risk Assessment
Risk Level: medium — While the partnership is positive, the drug is still in clinical development, and regulatory approval and market success are not guaranteed.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Registrant
- Pfizer Inc. (company) — Collaborator
- DYNE-251 (drug_candidate) — Therapeutic candidate for DMD
- Duchenne muscular dystrophy (DMD) (disease) — Target disease
- May 20, 2024 (date) — Announcement date
FAQ
What is the specific goal of the clinical collaboration between Dyne Therapeutics and Pfizer?
The collaboration aims to evaluate Dyne's novel antibody-oligonucleotide conjugate (AOC) therapeutic candidate, DYNE-251, for the treatment of Duchenne muscular dystrophy (DMD) in individuals with specific mutations.
What is the name of Dyne Therapeutics' therapeutic candidate being evaluated?
The therapeutic candidate is named DYNE-251.
What disease is DYNE-251 intended to treat?
DYNE-251 is intended to treat Duchenne muscular dystrophy (DMD).
When was this clinical collaboration announced?
The clinical collaboration was announced on May 20, 2024.
What type of therapeutic candidate is DYNE-251?
DYNE-251 is described as a novel antibody-oligonucleotide conjugate (AOC) therapeutic candidate.
Filing Stats: 2,135 words · 9 min read · ~7 pages · Grade level 13.1 · Accepted 2024-05-20 07:37:38
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share DYN Nasdaq Glob
Filing Documents
- d821973d8k.htm (8-K) — 52KB
- d821973dex991.htm (EX-99.1) — 45KB
- d821973dex992.htm (EX-99.2) — 52KB
- g821973ex99_2p10g1.jpg (GRAPHIC) — 259KB
- g821973ex99_2p11g1.jpg (GRAPHIC) — 317KB
- g821973ex99_2p12g1.jpg (GRAPHIC) — 150KB
- g821973ex99_2p13g1.jpg (GRAPHIC) — 249KB
- g821973ex99_2p14g1.jpg (GRAPHIC) — 341KB
- g821973ex99_2p15g1.jpg (GRAPHIC) — 278KB
- g821973ex99_2p16g1.jpg (GRAPHIC) — 356KB
- g821973ex99_2p17g1.jpg (GRAPHIC) — 285KB
- g821973ex99_2p18g1.jpg (GRAPHIC) — 225KB
- g821973ex99_2p19g1.jpg (GRAPHIC) — 281KB
- g821973ex99_2p1g1.jpg (GRAPHIC) — 395KB
- g821973ex99_2p20g1.jpg (GRAPHIC) — 318KB
- g821973ex99_2p21g1.jpg (GRAPHIC) — 322KB
- g821973ex99_2p22g1.jpg (GRAPHIC) — 326KB
- g821973ex99_2p23g1.jpg (GRAPHIC) — 280KB
- g821973ex99_2p24g1.jpg (GRAPHIC) — 215KB
- g821973ex99_2p25g1.jpg (GRAPHIC) — 273KB
- g821973ex99_2p26g1.jpg (GRAPHIC) — 203KB
- g821973ex99_2p27g1.jpg (GRAPHIC) — 282KB
- g821973ex99_2p28g1.jpg (GRAPHIC) — 226KB
- g821973ex99_2p29g1.jpg (GRAPHIC) — 388KB
- g821973ex99_2p2g1.jpg (GRAPHIC) — 743KB
- g821973ex99_2p30g1.jpg (GRAPHIC) — 356KB
- g821973ex99_2p31g1.jpg (GRAPHIC) — 305KB
- g821973ex99_2p32g1.jpg (GRAPHIC) — 349KB
- g821973ex99_2p33g1.jpg (GRAPHIC) — 307KB
- g821973ex99_2p34g1.jpg (GRAPHIC) — 328KB
- g821973ex99_2p35g1.jpg (GRAPHIC) — 165KB
- g821973ex99_2p36g1.jpg (GRAPHIC) — 155KB
- g821973ex99_2p37g1.jpg (GRAPHIC) — 292KB
- g821973ex99_2p38g1.jpg (GRAPHIC) — 292KB
- g821973ex99_2p39g1.jpg (GRAPHIC) — 289KB
- g821973ex99_2p3g1.jpg (GRAPHIC) — 221KB
- g821973ex99_2p40g1.jpg (GRAPHIC) — 209KB
- g821973ex99_2p41g1.jpg (GRAPHIC) — 320KB
- g821973ex99_2p42g1.jpg (GRAPHIC) — 275KB
- g821973ex99_2p43g1.jpg (GRAPHIC) — 221KB
- g821973ex99_2p44g1.jpg (GRAPHIC) — 336KB
- g821973ex99_2p45g1.jpg (GRAPHIC) — 259KB
- g821973ex99_2p46g1.jpg (GRAPHIC) — 310KB
- g821973ex99_2p47g1.jpg (GRAPHIC) — 393KB
- g821973ex99_2p4g1.jpg (GRAPHIC) — 315KB
- g821973ex99_2p5g1.jpg (GRAPHIC) — 255KB
- g821973ex99_2p6g1.jpg (GRAPHIC) — 509KB
- g821973ex99_2p7g1.jpg (GRAPHIC) — 231KB
- g821973ex99_2p8g1.jpg (GRAPHIC) — 375KB
- g821973ex99_2p9g1.jpg (GRAPHIC) — 292KB
- g821973g0520020025248.jpg (GRAPHIC) — 3KB
- g821973g0520020025474.jpg (GRAPHIC) — 1KB
- 0001193125-24-142232.txt ( ) — 19700KB
- dyn-20240520.xsd (EX-101.SCH) — 3KB
- dyn-20240520_lab.xml (EX-101.LAB) — 18KB
- dyn-20240520_pre.xml (EX-101.PRE) — 11KB
- d821973d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated May 20, 2024. 99.2 Presentation, dated May 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: May 20, 2024 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer